Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OTL-102
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Early clinical data support ex vivo hematopoietic stem cell gene therapy as a potentially promising treatment option for X-CGD.
Product Name : OTL-102
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 29, 2020
Lead Product(s) : OTL-102
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable